AIML.CN C$0.035 28 Mar 2026: AI/ML Innovations Inc CNQ research deal tests growth

The AIML.CN stock opened the trading session at C$0.035 after a -12.50% one-day move, as investors digest a research services agreement announced March 18, 2026. This deal sends NeuralCloud’s MaxYield™ ECG analytics into a Baker Heart and Diabetes Institute cardiovascular study. We examine how the agreement connects to revenue prospects, short-term volatility, and a conservative AI-driven valuation for AI/ML Innovations Inc (AIML.CN) on the Canadian Securities Exchange (CNQ) in Canada.

News snapshot: AIML.CN stock and the Baker Heart collaboration

AIML.CN stock moved to C$0.035 after NeuralCloud, a subsidiary of AI/ML Innovations Inc, signed a research services agreement with the Baker Heart and Diabetes Institute. The engagement will use the MaxYield™ platform for ECG signal processing in an HRV study; the work is non-diagnostic and aimed at academic publication. This news strengthens AIML.CN’s research services credentials but does not immediately add recurring revenue; the market reacted with a -12.50% intraday drop.

Financials and valuation: current metrics for AIML.CN stock

AI/ML Innovations reports EPS -0.03 and a trailing PE of -1.17, reflecting losses and a small revenue base. The company’s market capitalization is CAD 5,889,240.00 and shares outstanding are 168,264,000. Price averages sit at 50-day C$0.0373 and 200-day C$0.04605, while the 52-week range is C$0.03–C$0.12. These metrics point to early-stage scale, high valuation multiples like a price/sales of 35.00, and meaningful downside risk if commercial adoption lags.

Technical picture and trading flow for AIML.CN stock

Volume today was 340,181 versus an average 413,110, indicating below-average participation. Momentum indicators show RSI 45.06 and ADX 17.70, consistent with no clear trend. Short-term technicals imply limited buyer conviction while the stock trades below its 50-day and 200-day averages. Traders should note high relative volatility: one-year return is -46.15% and six-month return is -30.00%, highlighting swift moves on headline news.

Meyka AI grade and model forecast for AIML.CN stock

Meyka AI rates AIML.CN with a score out of 100: Meyka AI rates AIML.CN with a score of 61.99 / 100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of C$0.02 and a yearly price of C$0.02174. Versus the current C$0.035, the model implies a -42.86% downside to the monthly forecast and -37.60% to the yearly forecast. Forecasts are model-based projections and not guarantees.

Risks and catalysts shaping AIML.CN stock outlook

Primary risks include limited revenue, negative operating cash flow per share -0.02635, and narrow liquidity with market cap near CAD 5.89 million. Catalysts that could re-rate AIML.CN stock are: paid service contracts converting academic work into revenue, regulatory clarity for clinical use, and partnerships with hospitals or device makers. Sector headwinds in Healthcare digital services and stretched multiples relative to peers remain material.

Price targets, analyst view and sector context for AIML.CN stock

Consensus coverage is limited and in-house company rating shows C- (Strong Sell) as of 26 Mar 2026 on fundamental screens. Realistic near-term price targets range from a conservative C$0.02 to a bullish scenario near the 52-week high C$0.12 if commercialization accelerates. We set a cautious 12-month base case price target of C$0.03 and a downside stress target of C$0.02 given current cash and revenue profiles. The healthcare digital services sector shows mixed performance and tighter valuations than AIML.CN’s current multiples.

Final Thoughts

Key takeaways for AIML.CN stock: the market priced a -12.50% reaction to a research services deal that improves scientific validation but does not immediately expand recurring revenues. Financials show EPS -0.03, negative operating cash flow per share -0.02635, and tight liquidity with market cap around CAD 5,889,240.00. Meyka AI’s forecast model projects monthly C$0.02 and yearly C$0.02174, implying downside of -42.86% and -37.60% versus the current C$0.035; these projections are model-based and not guarantees. Investors focused on AI/ML and digital health should treat AIML.CN as a high-risk, speculative AI stock tied to research-to-commercial milestones. Watch for paid contracts from academic collaborations, clear commercial pilots, or improved trading liquidity before considering accumulation. For internal tracking, see the Meyka page for AIML.CN and the company filings for full disclosures Meyka AIML.CN. For the original research release, read the company statement on Nasdaq and the filing references at SEDAR+. Meyka AI provides this analysis as an AI-powered market analysis platform; grades and forecasts are informational and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.